171 related articles for article (PubMed ID: 31415103)
1. Interleukin-1 blockade treatment decreasing cardiovascular risk.
Zheng ZH; Zeng X; Nie XY; Cheng YJ; Liu J; Lin XX; Yao H; Ji CC; Chen XM; Jun F; Wu SH
Clin Cardiol; 2019 Oct; 42(10):942-951. PubMed ID: 31415103
[TBL] [Abstract][Full Text] [Related]
2. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events.
Abbate A; Van Tassell BW; Biondi-Zoccai GG
BioDrugs; 2012 Aug; 26(4):217-33. PubMed ID: 22571369
[TBL] [Abstract][Full Text] [Related]
3. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 blockade in cardiovascular diseases: a clinical update.
Buckley LF; Abbate A
Eur Heart J; 2018 Jun; 39(22):2063-2069. PubMed ID: 29584915
[TBL] [Abstract][Full Text] [Related]
5. Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.
Emmi G; Urban ML; Imazio M; Gattorno M; Maestroni S; Lopalco G; Cantarini L; Prisco D; Brucato A
Curr Cardiol Rep; 2018 Jun; 20(8):61. PubMed ID: 29904899
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory therapies were associated with reduced risk of myocardial infarction in patients with established cardiovascular disease or high cardiovascular risks: A systematic review and meta-analysis of randomized controlled trials.
Li Z; Lin C; Cai X; Hu S; Lv F; Yang W; Zhu X; Ji L
Atherosclerosis; 2023 Aug; 379():117181. PubMed ID: 37527612
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
[TBL] [Abstract][Full Text] [Related]
8. [IL-1 antagonists].
Kötter I; Horneff G
Z Rheumatol; 2010 Sep; 69(7):581-93. PubMed ID: 20703489
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
10. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
[TBL] [Abstract][Full Text] [Related]
12. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
Dinarello CA; Simon A; van der Meer JW
Nat Rev Drug Discov; 2012 Aug; 11(8):633-52. PubMed ID: 22850787
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6, but not C-reactive protein, predicts the occurrence of cardiovascular events after drug-eluting stent for unstable angina.
Chen SL; Liu Y; Lin L; Ye F; Zhang JJ; Tian NL; Zhang JX; Hu ZY; Xu T; Li L; Xu B; Latif F; Nguyen T
J Interv Cardiol; 2014 Apr; 27(2):142-54. PubMed ID: 24588086
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
[TBL] [Abstract][Full Text] [Related]
15. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
16. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
Ajala ON; Everett BM
Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
[TBL] [Abstract][Full Text] [Related]
18. Role of interleukin-1 inhibitors in the management of gout.
Tran TH; Pham JT; Shafeeq H; Manigault KR; Arya V
Pharmacotherapy; 2013 Jul; 33(7):744-53. PubMed ID: 23553601
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 as a therapeutic target in gout.
Dumusc A; So A
Curr Opin Rheumatol; 2015 Mar; 27(2):156-63. PubMed ID: 25633244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
